MaxCyte (MXCT) (GB:MXCT) has released an update.
MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leader in cell-engineering technology, has filed its Form 10-Q for Q1 2024 with the SEC, along with an 8-K form updating their corporate information. These documents detail the company’s performance and are accessible on both the SEC’s website and MaxCyte’s investor relations page. The company continues to innovate in the cell therapy market with its ExPERT platform, aimed at improving patient outcomes through advanced cell-based therapeutics.
For further insights into GB:MXCT stock, check out TipRanks’ Stock Analysis page.
